Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
21 nov. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been awarded a $3 million grant from the Gates...
New U.S. Department of Health and Human Services Campaign Joins HBCU Tour to Increase Flu, COVID-19 Vaccinations
10 sept. 2024 12h21 HE
|
Risk Less. Do More. Pan Respiratory Virus Public Education Campaign
Milwaukee, Wis., Sept. 10, 2024 (GLOBE NEWSWIRE) -- The U.S. Department of Health and Human Services’ (HHS) Risk Less. Do More. campaign is partnering with the HBCU Tailgate Tour to increase...
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Moderna, Inc. (NASDAQ: MRNA); Investors with Losses Encouraged to Discuss Their Options with Counsel
27 août 2024 12h10 HE
|
DiCello Levitt LLP
SAN DIEGO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of purchasers or acquirers of Moderna, Inc. (NASDAQ: MRNA) (“Moderna” or the “Company”) securities...
Airfinity US RSV vaccine market estimate cut by 64% from $4.7bn to $1.7bn a year by 2030 following recommendations for single lifetime shot for elderly people
24 juil. 2024 02h00 HE
|
Airfinity
London, England, July 24, 2024 (GLOBE NEWSWIRE) -- Airfinity has reduced its sales projections for vaccines against Respiratory Syncytial Virus (RSV) for older adults in the US from $4.7bn per year...
Foundation for Sarcoidosis Research and Walgreens Unite in Alabama to Boost Sarcoidosis Awareness and Spring Vaccine Education for April Awareness Month
15 avr. 2024 18h31 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research Partners with Walgreens in Alabama to Raise Awareness for Sarcoidosis and Spring Vaccines
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
06 févr. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a...
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
02 janv. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
12 déc. 2023 02h05 HE
|
Icosavax, Inc.
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
12 déc. 2023 02h00 HE
|
Icosavax, Inc.
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14 nov. 2023 16h05 HE
|
Icosavax, Inc.
- Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV - - IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023...